Akeso announces China NMPA accepts sNDA for ivonescimab in combo with chemotherapy to treat advanced squamous NSCLC
Akeso, Inc., a leading biopharmaceutical company announced that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with …